Vespa Capital has sold Cleeven to CNP
Cleeven has completed a secondary majority LBO with Compagnie Nationale à Portefeuille (CNP), a Belgian investment holding.
Cleeven is a European technology and IT consulting company with offices in France, Switzerland, Monaco and Sweden. The company offers the best human and technological skills within optimal timeframes.
Founded by Albert Frère, CNP manages net assets of around US$3 billion through a diversified portfolio of global companies that are leaders in their sectors. Backed by a stable and supportive family shareholder base, CNP focuses on long-term value creation through active involvement with the management teams of companies in which it participates.
Vespa Capital is an independent French private equity firm. Created in 2009, the management team is the first investor of the fund which systematically takes majority positions alongside entrepreneurs and management teams. Operating in the small-cap segment, Vespa Capital is specialized in primary transactions.
Oaklins’ team in France advised Cleeven on its secondary majority LBO.
Talk to the deal team
Related deals
Den Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Learn moreApollo Executive Search has entered into a strategic partnership with Schelstraete Delacourt
Apollo Executive Search, a Netherlands-based firm specialized in executive search services for mid-market private equity portfolio companies and technology scale-ups, has entered into a strategic partnership with Schelstraete Delacourt, a leading executive search, board search and executive assessment firm in the Benelux.
Learn moreBayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn more